Market Place
Sourcing Support
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib
28 Sep 2023 //
GLOBENEWSWIRE
Onconova Announces Dosing of First Participant in Phase 2 Trial of Rigosertib
25 May 2023 //
GLOBENEWSWIRE
Onconova Presents Data Characterizing Rigosertib Mechanisms of Action
07 Mar 2023 //
GLOBENEWSWIRE
Onconova Announces Updated Data from Investigator-sponsored Ph 1/2a Rigosertib
12 Sep 2022 //
GLOBENEWSWIRE
Onconova Announces Encouraging Clinical Data on Rigosertib-Nivolumab Combination
22 Sep 2021 //
GLOBENEWSWIRE
Onconova Submits Application For Rigosertib To Participate In Federally Funded
27 Jul 2020 //
PRESS RELEASE
Onconova Announces Publication Of Preclinical Data Supporting Rigosertib
23 Jul 2020 //
PRESS RELEASE
Onconova Therapeutics Announces Publication of Ph1 Results Oral Rigosertib
07 Jul 2020 //
GLOBENEWSWIRE
Onconova, STA Ink Exclusive License Agreement
18 Dec 2019 //
CONTRACT PHARMA
Stefan Fraenkel takes over as chief of Inceptua Group
12 Dec 2019 //
ENDPTS
Onconova`s Announces Presentation on Rigosertib at RAS-Targeted Drug Discovery
16 Sep 2019 //
GLOBENEWSWIRE
Onconova Submits SPA to FDA for Ph3 Trial of Oral Rigosertib+Azacitidine
03 Jan 2019 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.